Your browser doesn't support javascript.
loading
Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19.
Yan, Xiquan; Chen, Guoqiang; Jin, Zhaoxia; Zhang, Zhongwei; Zhang, Bing; He, Jiangming; Yin, Siqing; Huang, Juanshu; Fan, Maiying; Li, Zhenyuan; Chen, Fang; Zeng, Yong; Han, Xiaotong; Zhu, Yimin.
Afiliación
  • Yan X; Department of Emergency Medicine, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People's Hospital/The First Affiliated Hospital, Hunan Normal University, Changsha, Hunan, China.
  • Chen G; School of Life Sciences, Hunan Normal University, Changsha, Hunan, China.
  • Jin Z; Department of Laboratory Medicine, Huanggang Central Hospital, Huanggang, Hubei, China.
  • Zhang Z; Department of Cardiology, Huanggang Central Hospital, Huanggang, Hubei, China.
  • Zhang B; Department of Emergency Medicine, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People's Hospital/The First Affiliated Hospital, Hunan Normal University, Changsha, Hunan, China.
  • He J; Department of Laboratory Medicine, Huanggang Central Hospital, Huanggang, Hubei, China.
  • Yin S; Department of Public Health, Huangzhou General Hospital, Huanggang, Hubei, China.
  • Huang J; Department of Public Health, Huangzhou General Hospital, Huanggang, Hubei, China.
  • Fan M; Department of Respiratory and Critical Care Medicine, The Third Hospital of Changsha, Changsha, Hunan, China.
  • Li Z; Department of Emergency Medicine, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People's Hospital/The First Affiliated Hospital, Hunan Normal University, Changsha, Hunan, China.
  • Chen F; Department of Emergency Medicine, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People's Hospital/The First Affiliated Hospital, Hunan Normal University, Changsha, Hunan, China.
  • Zeng Y; Department of Emergency Medicine, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People's Hospital/The First Affiliated Hospital, Hunan Normal University, Changsha, Hunan, China.
  • Han X; Huanggang Central Hospital, Huanggang, Hubei, China.
  • Zhu Y; Department of Emergency Medicine, Hunan Provincial Institute of Emergency Medicine, Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Hunan Provincial People's Hospital/The First Affiliated Hospital, Hunan Normal University, Changsha, Hunan, China.
J Med Virol ; 94(1): 380-383, 2022 01.
Article en En | MEDLINE | ID: mdl-34403142
The durability of infection-induced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity has crucial implications for reinfection and vaccine effectiveness. However, the relationship between coronavirus disease 2019 (COVID-19) severity and long-term anti-SARS-CoV-2 immunoglobulin G (IgG) antibody level is poorly understood. Here, we measured the longevity of SARS-CoV-2-specific IgG antibodies in survivors who had recovered from COVID-19 1 year previously. In a cohort of 473 survivors with varying disease severity (asymptomatic, mild, moderate, or severe), we observed a positive correlation between virus-specific IgG antibody titers and COVID-19 severity. In particular, the highest virus-specific IgG antibody titers were observed in patients with severe COVID-19. By contrast, 74.4% of recovered asymptomatic carriers had negative anti-SARS-CoV-2 IgG test results, while many others had very low virus-specific IgG antibody titers. Our results demonstrate that SARS-CoV-2-specific IgG persistence and titer depend on COVID-19 severity.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Inmunoglobulina G / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Med Virol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Índice de Severidad de la Enfermedad / Inmunoglobulina G / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: J Med Virol Año: 2022 Tipo del documento: Article País de afiliación: China